Intent to Sole Source-Manufacture and Vialing of Influenza A/B SAR-CoV-2 Multiplex rRT-PCR Diagnostic Oligonuucleotide Primers and BHQnova Probes

The Centers for Disease Control and Prevention (CDC) 1600 Clifton Road NE, Atlanta Georiga, intends to award a sole source, firm fixed price contract to Biosearch Technologies for the manufacture and vialing of Influenza A/B SAR-CoV-2 multiplex rRT-PCR diagnostic oligonuucleotide primers and BHQnova probes. Production of the CDC Influenza A/B SARS-CoV-2 multiplex assay requires the use of proprietary BHQnova probes which are manufactured solely by Biosearch Technologies. Due to the proprietary nature of the BHQnova probes the CDC believes that Biosearch Technologies is the only vendor capable of meeting this requirement. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 41 U.S.C. 3304(a)(1). The North American Industry Classification System code for this procurement is 325414 –“Biological Product (except Diagnostic) Manufacturing”. Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive proposals; however, all responses received within fifteen (15) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the contract specialist Warren Hower at [email protected] by 5:00PM, January 4th 2021.